Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Overview
- Current Market Scenario
- Segmental Analysis
- Technological Advances
- Conclusion
Chapter 2 Market Overview
- Overview
- Biologic and Synthetic Drug Comparison
- Biologic Manufacturing
- Biopharmaceutical Manufacturing Process
- Macroeconomic Factors Analysis
- Porter’s Five Forces Analysis
- Supply Chain Analysis
- Cell and Gene Therapy Supply Chain
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Growing Demand for Biologics
- Rising Investments in Biopharmaceuticals
- Product Development Collaborations and Agreements
- Transition Toward Personalized Medicines
- Rising Aging Population and the Growing Prevalence of Chronic Diseases
- Market Restraints
- Emergence of Biosimilars
- Complex Manufacturing, Lack of Skilled Professionals and High Production Costs
- Market Opportunities
- Rising Demand for Biopharmaceuticals in Emerging Countries
- Technological Innovations in Biologics
Chapter 4 Regulatory Landscape
- U.S. Approval Process
- European Union Approval Process
- Asia-Pacific Approval Process
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies
- Advances in Monoclonal Antibodies
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Nanobodies
- Single-Chain Variable Fragments Antibodies
- Antibody Mimetics
- Antibody Fusion Proteins
- Advances in Vaccines
- Advances in Cell and Gene Therapies
Chapter 6 Market Segmentation Analysis
- Overview
- Segmentation Breakdown
- Market Analysis by Product Type
- Monoclonal Antibodies
- Vaccines
- Peptide Hormones
- Cell and Gene Therapy
- Others
- Market Analysis by Source Type
- Mammalian
- Microbial
- Others
- Market Analysis by Application
- Oncology
- Autoimmune Disease
- Infectious Diseases
- Others
- Geographic Breakdown
- Market Analysis by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Overview
- Highest Selling Biologic Therapeutic Drugs
- Market Share Analysis
- Monoclonal Antibodies
- Vaccines
- Peptide Hormones
- Cell and Gene Therapy
- Strategic Initiatives
- Agreements, Collaborations and Partnerships
- Acquisitions
- Other Strategies
Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective
- Introduction to ESG
- Sustainability Trends and Initiatives
- Environmental
- Social and Governance Initiatives
- ESG Risk Ratings
- Concluding Remarks
List of Tables
Summary Table: Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 1: Global Incidence and Mortality Cancer Rates, by the WHO Region, 2022
Table 2: Global Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 3: Top-Selling Monoclonal Antibodies, in 2023
Table 4: Global Market for Monoclonal Antibodies, by Region, Through 2029
Table 5: Global Market for Vaccines, by Region, Through 2029
Table 6: Global Market for Peptide Hormones, by Region, Through 2029
Table 7: Cell and Gene Therapy Approvals, 2023 and 2024
Table 8: Global Market for Cell and Gene Therapy, by Region, Through 2029
Table 9: Global Market for Other Biologic Drugs, by Region, Through 2029
Table 10: Global Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 11: Global Market for Mammalian Cells, by Region, Through 2029
Table 12: Global Market for Microbial Cells, by Region, Through 2029
Table 13: Global Market for Other Cells, by Region, Through 2029
Table 14: Global Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 15: Global Market for Biologic Therapeutic Drugs in Oncology, by Region, Through 2029
Table 16: Global Market for Biologic Therapeutic Drugs for Autoimmune Diseases, by Region, Through 2029
Table 17: Global Market for Biologic Therapeutic Drugs for Infectious Diseases, by Region, Through 2029
Table 18: Global Market for Biologic Therapeutic Drugs for Other Diseases, by Region, Through 2029
Table 19: Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 20: North American Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 21: North American Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 22: North American Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 23: North American Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 24: FDA-Approved Biologics, 2023
Table 25: European Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 26: European Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 27: European Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 28: European Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 29: Asia-Pacific Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 30: Asia-Pacific Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 31: Asia-Pacific Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 32: Asia-Pacific Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 33: Biologics Approved in China, in 2023
Table 34: Rest of the World Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 35: Rest of the World Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 36: Rest of the World Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 37: Rest of the World Market for Biologic Therapeutic Drugs, by Sub-Region, Through 2029
Table 38: Agreements, Collaborations and Partnerships in the Biologic Therapeutic Drug Market, 2022-2025
Table 39: Acquisitions in the Biologic Therapeutic Drug Market, 2022-2024
Table 40: Others Strategic Initiatives in the Biologic Therapeutic Drug Market, 2022-2024
Table 41: Environmental Initiatives by Various Biologic Therapeutic Drug Manufacturers
Table 42: Key Social and Governance Issues Biologic Therapeutic Drug Market
Table 43: ESG Risk Rankings for Biologic Therapeutic Drug Companies, 2023
Table 44: List of a Few Emerging Startups in the Biologic Therapeutic Drugs Market
Table 45: Information Sources in this Report
Table 46: Abbreviations Used in the Global Biologic Therapeutic Drugs Market
Table 47: AbbVie Inc.: Company Snapshot
Table 48: AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 49: AbbVie Inc.: Product Portfolio
Table 50: AbbVie Inc.: News/Key Developments, 2022-2024
Table 51: Amgen Inc.: Company Snapshot
Table 52: Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 53: Amgen Inc.: Product Portfolio
Table 54: Amgen Inc.: News/Key Developments, 2021-2024
Table 55: AstraZeneca: Company Snapshot
Table 56: AstraZeneca: Financial Performance, FY 2023 and 2024
Table 57: AstraZeneca: Product Portfolio
Table 58: AstraZeneca: News/Key Developments, 2021-2024
Table 59: Bristol-Myers Squibb Co.: Company Snapshot
Table 60: Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 61: Bristol-Myers Squibb Co.: Product Portfolio
Table 62: Bristol-Myers Squibb Co.: News/Key Developments, 2022-2025
Table 63: Eli Lilly and Co.: Company Snapshot
Table 64: Eli Lilly and Co.: Financial Performance, FY 2023 and 2024
Table 65: Eli Lilly and Co.: Product Portfolio
Table 66: Eli Lilly and Co.: News/Key Developments, 2023 and 2024
Table 67: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 68: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 69: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 70: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 71: Gilead Sciences Inc.: Company Snapshot
Table 72: Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 73: Gilead Sciences Inc.: Product Portfolio
Table 74: Gilead Sciences Inc.: News/Key Developments, 2022-2024
Table 75: GSK PLC.: Company Snapshot
Table 76: GSK PLC.: Financial Performance, FY 2023 and 2024
Table 77: GSK PLC.: Product Portfolio
Table 78: GSK PLC.: News/Key Developments, 2024
Table 79: Johnson & Johnson Services Inc.: Company Snapshot
Table 80: Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 81: Johnson & Johnson Services Inc.: Product Portfolio
Table 82: Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 83: Merck & Co. Inc.: Company Snapshot
Table 84: Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 85: Merck & Co. Inc.: Product Portfolio
Table 86: Merck & Co. Inc.: News/Key Developments, 2022-2024
Table 87: Novartis AG: Company Snapshot
Table 88: Novartis AG: Financial Performance, FY 2023 and 2024
Table 89: Novartis AG: Product Portfolio
Table 90: Novartis AG: News/Key Developments, 2022-2025
Table 91: Novo Nordisk A/S: Company Snapshot
Table 92: Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 93: Novo Nordisk A/S: Product Portfolio
Table 94: Novo Nordisk A/S: News/Key Developments, 2021-2025
Table 95: Pfizer Inc.: Company Snapshot
Table 96: Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 97: Pfizer Inc.: Product Portfolio
Table 98: Pfizer Inc.: News/Key Developments, 2023-2024
Table 99: Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 100: Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 101: Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 102: Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 103: Sanofi: Company Snapshot
Table 104: Sanofi: Financial Performance, FY 2023 and 2024
Table 105: Sanofi: Product Portfolio
Table 106: Sanofi: News/Key Developments, 2022-2024
List of Figures
Summary Figure: Global Market Shares of Biologic Therapeutic Drugs, by Region, 2023
Figure 1: Differences Between Synthetic and Biologic Drugs
Figure 2: Porter’s Five Forces Analysis of the Biologic Therapeutic Drugs Market
Figure 3: Supply Chain of Biopharmaceutical Drugs
Figure 4: Market Dynamics of Biologic Therapeutic Drugs
Figure 5: Venture Averages for Biopharma Therapeutics and Platform Companies, 2010-2024
Figure 6: Personalized Medicines’ Contribution to the Total FDA Approvals, 2015-2023
Figure 7: Emerging Technologies in Monoclonal Antibodies
Figure 8: Global Market Shares of Biologic Therapeutic Drugs, by Product Type, 2023
Figure 9: Global Vaccination Coverage, by Vaccine, 2023
Figure 10: Global Market Shares of Biologic Therapeutic Drugs, by Source Type, 2023
Figure 11: Global Market Shares of Biologic Therapeutic Drugs, by Application Type, 2023
Figure 12: Global Market Shares for Biologic Therapeutic Drugs, by Region, 2023
Figure 13: North American Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 14: European Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 15: Asia-Pacific Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 16: Rest of the World Market Shares of Biologic Therapeutic Drugs, by Sub-Region, 2023
Figure 17: Top 10 Blockbuster Biologic Therapeutic Drugs, by Sales Revenue, 2023
Figure 18: Global Market Shares for Monoclonal Antibodies, by Key Players, 2023
Figure 19: Global Market Shares for Vaccines, by Key Players, 2023
Figure 20: Global Market Shares for Peptide Hormones, by Key Players, 2023
Figure 21: Global Market Shares for Cell and Gene Therapy, by Key Players, 2023
Figure 22: AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 23: AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 24: Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 25: Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 26: AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 27: AstraZeneca: Revenue Share, by Region/Country, FY 2024
Figure 28: Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 29: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 30: Eli Lilly and Co.: Revenue Share, by Business Unit, FY 2024
Figure 31: Eli Lilly and Co.: Revenue Share, by Country/Region, FY 2024
Figure 32: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 33: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 34: Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35: Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 36: GSK PLC.: Revenue Share, by Business Unit, FY 2024
Figure 37: GSK PLC.: Revenue Share, by Country/Region, FY 2024
Figure 38: Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2024
Figure 39: Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2024
Figure 40: Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 41: Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 42: Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 43: Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 44: Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 45: Novo Nordisk A/S: Revenue Share by Country/Region, FY 2024
Figure 46: Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 47: Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 48: Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 49: Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 50: Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 51: Sanofi: Revenue Share, by Country/Region, FY 2024